期刊文献+

依托泊苷致严重过敏一例

下载PDF
导出
摘要 患者男,39岁。因右肺鳞癌行化疗于2012年11月9日入院。体格检查:脉搏62次/min,呼吸18次/min,血压140/86 mmHg(1 mmHg=0133 kPa)。既往无药物及食物过敏史。入院后考虑患者体质差给予基础抗肿瘤方案 EP 方案,应用依托泊苷、顺铂等化疗药物。化疗当天建立静脉通路后,给予09%氯化钠注射液250 mL,依托泊苷100 mg 静脉滴注,调节滴速至30滴/min,约2 min 后,患者出现面色青紫,胸闷,憋气,呼吸急促。查体:血压120/80 mmHg,脉搏60次/min,呼吸30次/min,心电监护示动脉血氧分压(SpO2)80%。立即停用依托泊苷,滴入5%葡萄糖注射液250 mL,给予吸氧,苯海拉明20 mg 肌肉注射,地塞米松10 mg 入壶,5 min后上述症状缓解,30 min 后症状消失。后患者调整化疗方案未再出现此种情况,故考虑为依托泊苷过敏。
作者 安纳 贾晓峰
出处 《山西医药杂志》 CAS 2014年第7期815-815,共1页 Shanxi Medical Journal
  • 相关文献

参考文献8

  • 1Smith AL, Haider K, S chachtner JM, et al. Fatal hemolysis after high-dose etoposide; is benzyl alcohol to blame[-J]. Pharmacother- apy, 2001,21(6) : 764-'766.
  • 2周际昌.实用肿瘤内科冶疗[M].北京:科学技术出版社,2010:61.
  • 3胡德建,毕恒太.静脉滴注依托泊苷致过敏反应1例[J].中国误诊学杂志,2007,7(29):7216-7216. 被引量:2
  • 4毕恒太,韩玉梅,常立军.静脉滴注足叶乙甙致过敏反应一例[J].中国药物与临床,2002,2(6):411-411. 被引量:1
  • 5牛志宏,冯云,陈骞,张爱军,孙贻娟.rFSH联合HP-hMG超促排卵方案中血清β-hCG水平与超促排卵结局关系初探[J].生殖与避孕,2012,32(9):578-581. 被引量:7
  • 6Van Voorhis BJ, Barnett M, Sparks AET, et al. Effect of the total motile sperm count on the efficacy and cost-effectiveness of intrauterine insemination and in vitro fertilization[J]. Fer- tility and Stenility, 2001, 75(4):661-668.
  • 7Platteau P, Smitz J, Albano C, et al. Exogenous luteinizing- hormone activity may influence the treatment outcome in in vitro fertilization but not in intracytoplasmic sperm injection- cyclesEJ:. Fertil Steril, 2004, 81(5):1401-1404.
  • 8Porter RN, Smith W, Craft I, et al. Induction of ovulation forin-vitro fertilization using buserelin and gonadotrophins[J]. Lancet, 1984, 2(1) :1284-1285.

二级参考文献8

  • 1Filicori M, Cognigni GE, Pocognoli P, et al. Modulation of folliculogenesis and steroidogenesis in women by graded menotropin administration. Hum Reprod, 2002, 17(9): 2009-15.
  • 2Kilani Z, Dakkak A, Ghunaim S, et al. A prospective, trial comparing highly purified hMG with recombinant FSH in women undergoing ICSI: ovarian response and clinical outcomes. Hum Reprod, 2003, 18(6): 1194-219.
  • 3Adonakis G, Deshpande N,Yates RW, et al. Luteinizing hor- mone increases estradiol secretion but has no effect on proges- terone concentrations in the late follicular phase of in vitro fertilization cycles in women treated with gonadotropin-re- leasing hormone agonist and follicle-stimulating hormone. Fertil Steril, 1998, 69(2):450-3.
  • 4Smitz J, Andersen AN, Devroey P, et al. Endocrine profile in serum and follicular fluid differs after ovarian stimulation with HP-hMG or recombinant FSH in patients. Hum Reprod, 2007, 22(3):676-87.
  • 5Andersen AN, Devroey P, Arce JC. Clinical outcome following stimulation with highly purified hMG or recombi- nant FSH in patients undergoing IVF: a randomized asses- sor-blind controlled trial. Hum Reprod, 2006, 21(12):3217- 27.
  • 6Lisi F, Rinaldi L, Fishel S, et al. Evaluation of two doses of recombinant luteinizing hormone supplementation in an unselected group of women undergoing follicular stimulation for in vitro fertilization. Fertil Steril, 2005, 83(2):309-15.
  • 7Rashidi BH, Sarvi F, Tehrani ES, et al. The effect ofhMG and recombinant human FSH on oocyte quality: a randomized single-blind clinical trial. Eur J Obstet Gynecol Reprod Biol, 2005, 120(1): 190-4.
  • 8Platteau P, Smitz J, Albano C, et al. Exogenous luteinizing hormone activity may influence the treatment outcome in in vitro fertilization but not in intracytoplasmic sperm injection cycles. Fertil Steril, 2004, 81(5):1401-4.

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部